GEN Exclusives

More »

GEN News Highlights

More »
May 14, 2008

Poniard Exercises Option to License Kinase Inhibitors from Scripps

  • Poniard Pharmaceuticals finalized an agreement with The Scripps Research Institute to license protein kinase inhibitors resulting from their almost three-year collaboration. In August 2005, Poniard (then NeoRx) forged a collaboration with Scripps focused on discovering small molecule, multitargeted, protein kinase inhibitors as therapeutic agents, including cancer treatments.

    Poniard gave Scripps $2.5 million over 26 months to support the research and retained an option to negotiate a worldwide, exclusive license to any compounds developed through the collaboration.

    "We are pleased with the productive collaboration with Scripps and we are continuing to build on the progress of this collaboration to identify compounds that have significant potential to treat cancer and other diseases," says Jerry McMahon, Ph.D., chairman and CEO of Poniard.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?